Key clinical point: Breast cancer patients presented with larger and more numerous brain metastases compared with non–small-cell lung cancer patients, but after brain-directed therapy, there were no differences in outcomes between groups.
Major finding: Median survival was 1.45 years for breast cancer patients and 1.09 for NSCLC patients.
Study details: A retrospective analysis of 349 patients with breast cancer and 659 patients with NSCLC treated between 2000 and 2015 at Dana-Farber/Brigham and Women’s Cancer Center.
Disclosures: The authors reported no conflicts of interest.
Source: Cagney DN et al. JAMA Oncol. 2018 May 17. doi: 10.1001/jamaoncol.2018.0813.
Cagney DN et al. JAMA Oncol. 2018 May 17. doi: 10.1001/jamaoncol.2018.0813.
This Week's Must Reads
New model guides treatment decisions in mRCC, Armstrong AJ et al. Ann Oncol. 2018 Sep 10. doi: 10.1093/annonc/mdy406
mRCC: Jaw osteonecrosis increased with denosumab/antiangiogenics, Guillot A et al. Clin Genitourin Cancer. 2018 Sep 6. doi: 10.1016/j.clgc.2018.08.006.
Brazilian study: TKIs effective in clear cell RCC, Velho PI et al. J Glob Onc. 2018 Sep 10. doi: 10.1200/JGO.18.00073.
SBRT safe, effective in oligometastatic RCC, Franzese et al. J Urol. 2018 Sep 1. doi: 10.1016/j.juro.2018.08.049.
CRP levels and RCC prognosis, Nakayama T et al. Clin Genitourin Cancer. 2018 Aug 11. doi: 10.1016/j.clgc.2018.07.027.
Must Reads in Breast Cancer
Inherited mutations account for 12% of Nigerian breast cancer, Olopade et al. J Clin Oncol. 2018 Aug 21. doi: 10.1200/JCO.2018.78.3977.
Study could clarify CTC-based staging of metastatic breast cancer , Davis A et al. ASCO 2018 Poster 1019.
Taselisib and fulvestrant fall short in advanced ER+/HER2- breast cancer, Baselga et al. ASCO Abstract LBA1006.
Brain met outcomes similar for NSCLC, breast cancer patients, Cagney DN et al. JAMA Oncol. 2018 May 17. doi: 10.1001/jamaoncol.2018.0813.
Ketorolac during primary breast cancer surgery bettered diclofenac, Desmedt C et al. J Natl Cancer Inst. 2018 Apr 30. doi: 10.1093/jnci/djy042.